Top

Published in:

01-05-2007 | Original Article

Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas

Authors: Katalin Borka, Péter Kaliszky, Erzsébet Szabó, Gábor Lotz, Péter Kupcsulik, Zsuzsa Schaff, András Kiss

Published in: Virchows Archiv | Issue 5/2007

Abstract

Altered expression of recently described claudins (CLDNs) as members of tight junction (TJ) transmembrane proteins was noted in several malignancies. We aimed to analyze protein and messenger RNA (mRNA) expressions of different CLDNs in human pancreatic endocrine tumors (PET) and ductal adenocarcinomas. A total of 45 formalin-fixed, paraffin-embedded samples were studied. Immunohistochemistry and real-time reverse transcriptase polymerase chain reaction analysis were carried out for quantification of CLDN 1, -2, -3, -4, and -7 expressions. Normal acini and ducts showed strong CLDNs 1, -3, -4, and -7 and scattered CLDN 2 protein expressions, while Langerhans islands revealed only CLDN 3 and -7 expressions. CLDN 2 expression was found in the half of ductal adenocarcinomas, while the vast majority of endocrine tumors were negative. CLDN 1, -4, and -7 immunohistochemistry was positive in all adenocarcinomas, whereas endocrine tumors were completely negative for CLDNs 1 and -4. CLDN 3 and -7 proteins were detected in all endocrine tumors, while CLDN 3 in ductal adenocarcinomas was negative. The mRNA expression of CLDNs showed differences between endocrine tumors and ductal adenocarcinomas, similar as found for protein expression. Our findings support that PET and ductal carcinomas are specifically characterized by different expression pattern of CLDNs. High expressions of CLDN 3 in endocrine tumors and CLDN 4 in ductal carcinomas might attract them as targets for adjuvant therapy.

Arnold R, Rinke A, Schmidt Ch, Hofbauer L (2005) Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 19:649–656PubMedCrossRef

Aung PP, Mitani Y, Sanada Y, Nakayama H, Matsusaki K, Yasui W (2006) Differential expression of claudin-2 in normal human tissues and gastrointestinal carcinomas. Virchows Arch 448:428–434PubMedCrossRef

Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P (2006) Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11:612–623PubMedCrossRef

Collares-Buzato CB, Carvalho CPF, Furtado AG, Boschero AC (2004) Upregulation of the expression of tight and adherens junction-associated proteins during maturation of neonatal pancreatic islets in vitro. J Mol Histol 35:811–822PubMedCrossRef

Dhawan P, Singh AB, Deane NG et al (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776PubMedCrossRef

Ezzat S, Asa SL (2005) The molecular pathogenetic role of cell adhesion in endocrine neoplasia. J Clin Pathol 58:1121–1125PubMedCrossRef

Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550PubMedCrossRef

Győrffy H, Holczbauer Á, Nagy P, Szabó Z, Kupcsulik P, Páska C, Papp J, Schaff Z, Kiss A (2005) Claudin expression in Barrett’s esophagus and adenocarcinoma. Virchows Arch 447:961–968PubMedCrossRef

Halász J, Holczbauer Á, Páska C, Kovács M, Benyó G, Verebély T, Schaff Z, Kiss A (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Hum Pathol 37:555–561PubMedCrossRef

10.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Van den Bergh PM, Hacker NF, Sutherland RL, O’Brien PM (2004) Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10:4427–4436PubMedCrossRef

11.

Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B (1998) Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology 45:855–866PubMed

12.

Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186PubMedCrossRef

13.

House MG, Schulick RD (2006) Endocrine tumors of the pancreas. Curr Opin Oncol 18:23–29PubMedCrossRef

14.

Jacobs AD (2002) Gemcitabine-based therapy in pancreas cancer: gemcitabine–docetaxel and other novel combinations. Cancer 95(Suppl):923–927CrossRef

15.

Kaifi JT, Heidtmann S, Schurr PG, Reichelt U, Mann O, Yekebas EF, Wachowiak R, Strate T, Schachner M, Izbiczki JR (2006) Absence of L1 in pancreatic masses distinguishes adenocarcinomas from poorly differentiated neuroendocrine carcinomas. Anticancer Res 26:1167–1170PubMed

16.

Kloppel G (2003) Tumors of the endocrine pancreas. Pathologe 24:265–271PubMedCrossRef

17.

Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033PubMedCrossRef

18.

Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK (2005) Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep 3:193–199CrossRef

19.

Lodi Cs, Szabo E, Holczbauer Á, Batmunkh E, Szijarto A, Kupcsulik P, Kovalszky I, Paku S, lllyés G, Kiss A, Schaff Zs (2006) Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod Path 19:460–469CrossRef

20.

Long H, Crean CD, Lee WH, Cummings OW, Gabig TG (2001) Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61:7878–7881PubMed

21.

Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Lohr M, Leder G, Iwamura T, Adler G, Gress TM (2003) Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 63:6265–6271PubMed

22.

Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121:226–230PubMedCrossRef

23.

Nishimura M, Kaltizaki M, Ono Y, Morimoto K, Takeuchi M, Inoue Y, Imai T, Takayi Y (2001) JEAP, a novel component of tight junctions in exocrine cells. J Biol Chem 277:5583–5587PubMedCrossRef

24.

Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA, Kohleisen B (2005) Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunotheras 54:431–445CrossRef

25.

Orci L, Malaisse-Lagae F, Amherdt M, Ravazzola M, Weisswange A, Dobbs R, Perrelet A, Unger R (1975) Cell contacts in human islets of Langerhans. J Clin Endocrinol Metab 41(5):841–844 (Nov)PubMedCrossRef

26.

Páska C, Bögi K, Szilák L, Tőkés AM, Szabó E, Sziller I, Rigó J Jr, Sobel G, Szabó I, Kaposi-Novák P, Kiss A, Schaff Z (2004) Effect of formalin, acetone, and RNAlater fixatives on tissue preservation and different size amplicons by real-time PCR from paraffin-embedded tissue. Diagn Mol Pathol 13:234–240PubMedCrossRef

27.

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36PubMedCrossRef

28.

Rahner C, Mitic LL, Anderson JM (2001) Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120:411–422PubMedCrossRef

29.

Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567–2575PubMed

30.

Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80 (Suppl 1):12–15PubMedCrossRef

31.

Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, Yeo CJ, Hruban RH, Goggins M (2004) Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164:903–914PubMed

32.

Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, Chiba H (2003) Tight junctions and human diseases. Med Electron Microsc 36:147–156PubMedCrossRef

33.

Schmitt M, Klonowski-Stumpe H, Eckert M, Luthen R, Haussinger D (2004) Disruption of paracellular sealing is an early event in acute caerulein-pancreatitis. Pancreas 28:181–190PubMedCrossRef

34.

Sobel G, Páska C, Szabó I, Kiss A, Kádár A, Schaff Z (2005) Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169PubMedCrossRef

35.

Sobel G, Németh J, Kiss A, Lotz G, Szabó I, Udvarhelyi N, Schaff Z, Páska C (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103:591–598PubMedCrossRef

36.

Sobel G, Szabó I, Páska C, Kiss A, Kovalszky I, Kádár A, Paulin F, Schaff Z (2005) Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathol Oncol Res 11:26–31PubMedCrossRef

37.

Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 46:551–560PubMedCrossRef

38.

Soini Y, Tommola S, Helin H, Martikainen P (2006) Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch 448:52–58PubMedCrossRef

39.

Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, Tsukita S (1999) Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 147:195–204PubMedCrossRef

40.

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160:1745–1754PubMed

41.

Tőkés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Zs (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305PubMedCrossRef

42.

Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A (2005) Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int 55:63–69PubMedCrossRef

43.

Tsukita S, Furuse M (1998) Overcoming barriers in the study of tight junction functions: from occludin to claudin. Genes Cells 3:569–573PubMedCrossRef

44.

Turksen K, Troy TC (2004) Barriers built on claudins. J Cell Sci 117:2435–2447PubMedCrossRef

45.

Van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH (2006) The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas 32:396–402PubMedCrossRef

46.

Viola KV, Sosa JA (2005) Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol 17:24–27PubMedCrossRef

Title: Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas
Authors: Katalin Borka
Péter Kaliszky
Erzsébet Szabó
Gábor Lotz
Péter Kupcsulik
Zsuzsa Schaff
András Kiss
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 5/2007
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0406-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2007

Tissue preparation for MOHS’ frozen sections: a comparison of three techniques

Pulmonary “inflammatory myofibroblastic” tumors: a critical examination of the diagnostic category based on quantitative immunohistochemical analysis

“Benign” metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung

Epithelial misplacement in the muscularis propria after biopsy of a colonic adenoma

A novel myoepithelial/progenitor cell marker in the breast?

Skp2 expression is associated with down-regulation of p27 protein and cell proliferation in salivary adenoid cystic carcinoma